需体外循环的肝素诱导血小板减少症患者实践模式调查
该调查通过在线问卷收集了304份来自心血管麻醉医师协会(SCA)和体外技术协会(AmSECT)成员的回复,旨在描述需要体外循环(CPB)的肝素诱导血小板减少症(HIT)患者的诊断与管理实践趋势。结果显示,多数受访者使用临床病史和/或抗体检测诊断HIT,75%报告使用机构方案,比伐卢定是最常用的替代抗凝策略(75%),且多数(83%)使用活化凝血时间(ACT)监测抗凝。
要点
- 多数受访者使用临床病史和/或抗体检测诊断HIT。
- 75%的受访者报告其机构有针对HIT-CPB病例的方案或指南。
- 比伐卢定是最常用的替代抗凝策略(75%),多数使用ACT监测。
核心结论
- 大多数回复的SCA和AmSECT成员报告其机构使用HIT/CPB病例的方案或指南,且多数指南指导使用比伐卢定作为替代抗凝剂。
研究设计与样本
- 通过在线调查工具对SCA和AmSECT成员进行问卷调查,共收到304份完整回复(回复率5.8%),其中75%由麻醉医师完成,24%由灌注师完成。
主要发现
- 多数受访者使用临床病史(71%)和/或抗体检测(63%)诊断HIT。
- 75%的受访者报告使用机构方案处理HIT-CPB病例。
- 89%的受访者报告过去3年内至少处理过1例HIT-CPB病例,总病例经验至少785例。
- 比伐卢定是最常用的替代抗凝策略(75%),83%的受访者使用ACT监测抗凝。
- 其他方法如血浆置换也被成功用于该患者群体。
临床怎么用
- 对于需CPB的HIT患者,可参考机构方案使用比伐卢定作为替代抗凝剂,并用ACT监测抗凝。
局限性
- 回复率较低(5.8%),可能存在无应答偏倚。
- 调查结果基于受访者自我报告,可能无法完全反映实际临床实践。
- 需要进一步研究包括替代抗凝策略的比较研究以确定最佳方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse reaction to heparin. Patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) are routinely anticoagulated with heparin before the initiation of bypass. Heparin is contraindicated, however, in patients with acute HIT, and alternatives to routine practice are often used. While guidelines have recently been published addressing this topic 10, there remains variance between institutions in how these cases are treated. Our goal was to better delineate practice trends in the diagnosis and management of HIT patients requiring CPB. METHODS: We surveyed members of the Society of Cardiovascular Anesthesiologists (SCA) and the American Society for Extracorporeal Technology (AmSECT) using an online survey tool. RESULTS: We received 304 completed surveys (5.8% response rate), 75% completed by an anesthesiologist, and 24% by a perfusionist. The majority of respondents used clinical history and/or antibody testing (71% and 63%, respectively) to diagnose HIT. Seventy-five percent of respondents reported using an institutional protocol for HIT-CPB cases. Most respondents (89%) reported having at least 1 case in the last 3 years, with a total case experience of at least 785 cases (785 = the minimum number of cases in each case volume category × the number of respondents choosing that category). The strategy recommended in published guidelines, bivalirudin, was the most commonly reported alternative anticoagulation strategy (75%) used by respondents in HIT cases, with most (83%) using the activated clotting time (ACT) to monitor anticoagulation. CONCLUSIONS: Most responding SCA and AmSECT members reported that their institution used a protocol or guideline for HIT/CPB cases, and most guidelines directed the use of bivalirudin as an alternative anticoagulant. Various other methods such as plasmapheresis are also being used with success in this patient population. Further research, including comparison studies of alternative anticoagulant strategies, is required to elucidate the best approach to these difficult cases.
引用
- Wanat-Hawthorne A, Tanaka K, Angona R, et al. Survey of Practice Pattern in Patients With Heparin-Induced Thrombocytopenia Requiring Cardiopulmonary Bypass. Anesth Analg. 2021. PMID: 34415867. doi:10.1213/ANE.0000000000005721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。